866-997-4948(US-Canada Toll Free)

Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 48 Pages

Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2017, provides an overview of the Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline landscape.

Oral herpes is an infection of the lips, mouth, or gums due to the herpes simplex virus. Oral herpes is also called herpes labialis. Symptoms include sore throat, fever, swollen glands and painful swallowing. Treatment includes antiviral medications.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Herpes Labialis (Oral Herpes) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Herpes Labialis (Oral Herpes) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Herpes Labialis (Oral Herpes) - Overview 6
Herpes Labialis (Oral Herpes) - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Herpes Labialis (Oral Herpes) - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development 20
AiCuris GmbH & Co KG 20
Beech Tree Labs Inc 20
NanoViricides Inc 20
Onxeo SA 21
Shulov Innovative Science Ltd 21
Vironova AB 21
Herpes Labialis (Oral Herpes) - Drug Profiles 23
acyclovir - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Aspidasept - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
B-220 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
BTL-TMLHSV - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
herpes simplex virus [type 1, 2] vaccine - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
pritelivir - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecule for Cold Sores - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
squaric acid dibutyl ester - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ZEP-3 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Herpes Labialis (Oral Herpes) - Dormant Projects 37
Herpes Labialis (Oral Herpes) - Discontinued Products 38
Herpes Labialis (Oral Herpes) - Product Development Milestones 39
Featured News & Press Releases 39
Aug 23, 2017: AiCuris Announces Final Patient Treated in Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes 39
May 24, 2017: Cold Sore Treatment Developed by Squarex Shown Effective by Immunotherapy Study 39
Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes 40
Feb 16, 2016: Cipher Pharmaceuticals announces Sitavig accepted for review by Health Canada 40
Jul 21, 2014: BioAlliance Pharma announces the launch of Sitavig in the United States by its partner Innocutis and the granting of a new U.S. Sitavig patent 41
Jul 10, 2013: BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants 41
May 27, 2013: BioAlliance Pharma Presents Results Of Sitavig At 10th EADV Symposium 42
Apr 15, 2013: BioAlliance Pharmas Sitavig Receives US Marketing Authorization For Treatment Of Herpes Labialis 42
Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial 43
Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig 43
May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier 44
Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure 44
Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis 45
Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting 45
Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables
Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products under Development by Universities/Institutes, H2 2017 9
Products under Development by Companies, H2 2017 10
Products under Development by Universities/Institutes, H2 2017 11
Number of Products by Stage and Target, H2 2017 13
Number of Products by Stage and Mechanism of Action, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Herpes Labialis (Oral Herpes) - Pipeline by AiCuris GmbH & Co KG, H2 2017 20
Herpes Labialis (Oral Herpes) - Pipeline by Beech Tree Labs Inc, H2 2017 20
Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides Inc, H2 2017 21
Herpes Labialis (Oral Herpes) - Pipeline by Onxeo SA, H2 2017 21
Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd, H2 2017 21
Herpes Labialis (Oral Herpes) - Pipeline by Vironova AB, H2 2017 22
Herpes Labialis (Oral Herpes) - Dormant Projects, H2 2017 37
Herpes Labialis (Oral Herpes) - Discontinued Products, H2 2017 38

List of Figures
Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products by Targets, H2 2017 12
Number of Products by Stage and Targets, H2 2017 12
Number of Products by Mechanism of Actions, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 16
Number of Products by Stage and Routes of Administration, H2 2017 16
Number of Products by Molecule Types, H2 2017 18
Number of Products by Stage and Molecule Types, H2 2017 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *